| ¿µ¹® | dumping syndrome | ÇÑ±Û | ´ýÇÎÁõÈıº |
|---|---|---|---|
| ¼³¸í | ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº ȯÀÚ¿¡°Ô¼ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼ ÀÛÀºÃ¢ÀÚ·Î Ãß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒȰüÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇÏ°Ô ´Ã¾î³ªµç°¡, ÈÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒȰüÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾÙ. ÁÖ·Î ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù. |
||
| ¿µ¹® | Raynaud syndrome | ÇÑ±Û | ·¹À̳ëÁõÈıº |
|---|---|---|---|
| ¼³¸í | »çÁöÀÇ ´ëĪÀû û»öÁõÀ» Ư¡À¸·Î ÇÏ´Â Áõ»óÀ¸·Î¼ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î û»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù. |
||
| ¿µ¹® | battered child syndrome | ÇÑ±Û | ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ ½ÅüÀûÀÎ Çд븦 ¹Þ¾Æ ¹ß»ýÇÏ´Â °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »óó¸¦ ¹ÞÀº ½Ã±â°¡ ¼·Î Â÷À̰¡ ÀÖ´Â ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼ °üÂûµÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀÎ °æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³, ¹ÝÇ×Àû ŵµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄÚ¿Ã Áßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼´Â ºó°ï, ºÎºÎ ºÒÈ, ÇÙ°¡Á·ÀÌ¸é¼ »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | severe acute respiratory syndrome(SARS) | ÇÑ±Û | »ç½º |
|---|---|---|---|
| ¼³¸í | Áß±¹ ±¤µ¿ Áö¿ª¿¡¼ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â ȯÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â ħ¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀÇ È£Èí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. ħ¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇÏ´Ù´Â ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. |
||
| ¿µ¹® | congenital rubella syndrome | ÇÑ±Û | ¼±ÃµÇ³ÁøÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀӽűⰣ Áß¿¡ »ê¸ð°¡ dzÁø¿¡ °É¸®¸é ÀÌ Ç³Áø ¹ÙÀÌ·¯½º´Â ŹÝÀ» ÅëÇØ¼ žƿ¡°Ô Àü´ÞµÇ¾î¼ žÆÀÇ Ç³Áø°¨¿°À» ÀÏÀ¸Å²´Ù. ÀӽŠù 3°³¿ù µ¿¾È, ƯÈ÷ ÀӽŠù´Þ¿¡ žư¡ dzÁøÀÇ °¨¿°À» ¹ÞÀ¸¸é, ½Å»ý¾Æ¿¡¼ ¼±Ãµ±âÇü, Áï ´«¿¡¼ ÃÐÁ¡À» Á¤È®È÷ ¸ÂÃß¾îÁÖ´Â ·»ÁîÀÇ ¿ªÇÒÀ» ÇÏ´Â ¼öÁ¤Ã¼ÀÇ È¥Å¹(¹é³»Àå), ½ÉÀå±âÇü, ±Í¸Ó°Å¸® ¹× ½ÉÇÑ Áö´É¹Ú¾àÀ» µ¿¹ÝÇÏ´Â ¼ÒµÎÁõ µîÀÌ ¹ß»ýÇÏ´Â ¼ö°¡ ¸¹´Ù. |
||
| MEA-I | multiple endocrine adenomatosis type I |
|---|---|
| MEN | multiple endocrine neoplasia |
| MEN-I | multiple endocrine neoplasia, type I |
| MCS | malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| endocrine surgical procedures | Surgery performed on any endocrine gland. (12 Dec 1998) |
|---|---|
| endocrine system | The system of glands that release their secretions (hormones) directly into the circulatory system. In addition to the endocrine glands, included are the chromaffin system and the neurosecretory systems. (12 Dec 1998) |
| tuberculosis, endocrine | Tuberculous infection of the endocrine glands. (12 Dec 1998) |
| abdominal muscle deficiency syndrome | <syndrome> Congenital absence (partial or complete) of abdominal muscles, in which the outline of the intestines is visible through the protruding abdominal wall; in males, genitourinary anomalies (urinary tract dilation and cryptorchidism) are also found; genetics unclear. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| carbonic anhydrase II deficiency syndrome | <syndrome> An inherited deficiency of carbonic anhydrase II that results in osteopetrosis and metabolic acidosis. Synonym: osteopetrosis with renal tubular acidosis. (05 Mar 2000) |
| cellular immunity deficiency syndrome | <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind. See: immunodeficiency. (05 Mar 2000) |
| corpus luteum deficiency syndrome | <syndrome> Functional disturbances caused by insufficient ovarian luteinization; reflected by inadequate luteal phase endometrial response. (05 Mar 2000) |
| polyendocrine deficiency syndrome | <syndrome> Polyglandular deficiency syndrome, associated pathologic dysfunction of several endocrine glands, as in Schmidt's syndrome. (05 Mar 2000) |
| 17-hydroxylase deficiency syndrome | <syndrome> Congenital deficiency of adrenocortical, and possibly ovarian, steroid C-17a hydroxylase; the resulting excessive secretion of corticosterone and deoxycorticosterone produces hypertension and hypokalaemic alkalosis; absence of aldosterone secretion in such patients may indicate a multiple enzymic deficiency. (05 Mar 2000) |
| leukocyte-adhesion deficiency syndrome | <syndrome> Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (receptors, leukocyte-adhesion) comprising the CD11/CD18 family of glycoproteins. The syndrome is characterised by abnormal adhesion-dependent functions, especially defective tissue emigration of neutrophils, leading to recurrent infection. (12 Dec 1998) |
| abortion, multiple | Couples who have had 2 or more miscarriages (spontaneous abortions) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages. (12 Dec 1998) |
| advanced multiple-beam equalization radiography | A variant of scanning equalization radiography using several X-ray beams. (05 Mar 2000) |
| amyloidosis of multiple myeloma | Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known. (05 Mar 2000) |
| cancer, multiple myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|